BRPI0408876A - derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer - Google Patents

derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer

Info

Publication number
BRPI0408876A
BRPI0408876A BRPI0408876-0A BRPI0408876A BRPI0408876A BR PI0408876 A BRPI0408876 A BR PI0408876A BR PI0408876 A BRPI0408876 A BR PI0408876A BR PI0408876 A BRPI0408876 A BR PI0408876A
Authority
BR
Brazil
Prior art keywords
treating
substituted
unsubstituted
tumor
indazole derivative
Prior art date
Application number
BRPI0408876-0A
Other languages
English (en)
Inventor
Yoshihisa Ohta
Fumihiko Kanai
Shinji Nara
Yutaka Kanda
Hiroshi Umehara
Yukimasa Shiotsu
Tomoki Naoe
Hitoshi Kiyoi
Keiko Kawashima
Hiromi Ando
Motoki Miyama
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of BRPI0408876A publication Critical patent/BRPI0408876A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADO DE INDAZOL, COMPOSIçãO FARMACêUTICA, AGENTES ANTI-TUMORAL E TERAPêUTICO, USO DO DERIVADO DE INDAZOL OU DO SEU SAL FARMACEUTICAMENTE ACEITáVEL, E, MéTODOS PARA TRATAR DE TUMOR, PARA TRATAR DE LEUCEMIA, PARA TRATAR DE MIELOMA OU LINFOMA, PARA TRATAR DE CARCINOMA SóLIDO E PARA TRATAR DE CáNCER". Derivados de indazol representados pela fórmula geral (I) ou seus sais farmacologicamente aceitáveis: (I) em que R¬ 1¬ é CONR¬ 1a¬R¬ 1b¬ (R¬ 1a¬ e R¬ 1b¬ São , cada um independentemente, hidrogênio, alquila inferior, arila, aralquila ou um grupo heterocíclico, ou R¬ 1a¬ e R¬ 1b¬ juntos com o átomo de nitrogênio adjacente podem formar um grupo heterocíclico) ou coisa parecida; e R¬ 2¬ é hidrogênio, CONR¬ 2a¬R¬ 2b¬ (em que R¬ 2a¬ e R¬ 2b¬ São como definido para R¬ 1a¬ e R¬ 1b¬), NR¬ 2c¬R¬ 2d¬ (em que R¬ 2c¬ e R¬ 2d¬ São, cada um independentemente, hidrogênio, alquila inferior, alcanoíla inferior, aroíla, heteroaroíla, aralquila, alquilsulfonila ou arilsulfonila) ou coisa parecida.
BRPI0408876-0A 2003-07-30 2004-07-30 derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer BRPI0408876A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003203508 2003-07-30
PCT/JP2004/011287 WO2005012257A1 (ja) 2003-07-30 2004-07-30 インダゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0408876A true BRPI0408876A (pt) 2006-04-11

Family

ID=34113614

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408876-0A BRPI0408876A (pt) 2003-07-30 2004-07-30 derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer

Country Status (15)

Country Link
US (2) US7470717B2 (pt)
EP (1) EP1652842B1 (pt)
JP (1) JP4335212B2 (pt)
KR (1) KR20060119705A (pt)
CN (1) CN100390149C (pt)
AT (1) ATE553092T1 (pt)
AU (1) AU2004260756B2 (pt)
BR (1) BRPI0408876A (pt)
CA (1) CA2518950A1 (pt)
EA (1) EA010165B1 (pt)
ES (1) ES2384568T3 (pt)
MX (1) MXPA05011420A (pt)
NO (1) NO20055333L (pt)
WO (1) WO2005012257A1 (pt)
ZA (1) ZA200509952B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007270B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н.В. Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
CA2476067C (en) 2002-03-13 2011-09-20 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
ES2306880T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa.
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
AU2004260756B2 (en) * 2003-07-30 2010-03-25 Kyowa Hakko Kirin Co., Ltd. Indazole derivatives
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
EP1847532B1 (en) * 2005-01-27 2013-06-05 Kyowa Hakko Kirin Co., Ltd. Igf-1r inhibitor
JP4975616B2 (ja) * 2005-04-28 2012-07-11 協和発酵キリン株式会社 インダゾール−３−イルメチルホスホニウム塩の製造法
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
EP1943232B1 (en) 2005-10-27 2011-05-18 Janssen Pharmaceutica NV Squaric acid derivatives as inhibitors of histone deacetylase
CA2635015C (en) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
US8101616B2 (en) 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
DE602007001190D1 (de) 2006-01-19 2009-07-09 Janssen Pharmaceutica Nv Aminophenylderivate als neue inhibitoren von histondeacetylase
US20090209537A1 (en) * 2006-06-30 2009-08-20 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitors
WO2008001885A1 (en) 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Abl KINASE INHIBITOR
JPWO2008020606A1 (ja) * 2006-08-16 2010-01-07 協和発酵キリン株式会社 血管新生阻害剤
GB0619325D0 (en) 2006-09-30 2006-11-08 Univ Strathclyde New compounds
CA2680161A1 (en) 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103804306A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US11629139B2 (en) 2017-09-08 2023-04-18 President And Fellows Of Harvard College Small molecule inhibitors of Ebola and Lassa fever viruses and methods of use
EA202190170A1 (ru) * 2018-07-23 2021-08-13 Селджен Квонтисел Рисёрч, Инк. Способ получения ингибитора бромодомена
WO2024052684A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Antibody drug conjugate comprising nmt inhibitor and its use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232059A (ja) * 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7238853B2 (en) * 2000-07-14 2007-07-03 Unicrop Ltd Molecular mechanisms for gene containment in plants
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
KR20050004214A (ko) * 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
EP1582211A1 (en) * 2002-12-03 2005-10-05 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
AU2004260756B2 (en) * 2003-07-30 2010-03-25 Kyowa Hakko Kirin Co., Ltd. Indazole derivatives

Also Published As

Publication number Publication date
ZA200509952B (en) 2006-09-27
AU2004260756A1 (en) 2005-02-10
JPWO2005012257A1 (ja) 2006-09-14
WO2005012257A1 (ja) 2005-02-10
CN1777590A (zh) 2006-05-24
ES2384568T3 (es) 2012-07-09
EP1652842A4 (en) 2008-10-01
NO20055333L (no) 2005-11-11
US7919517B2 (en) 2011-04-05
CN100390149C (zh) 2008-05-28
US20090082348A1 (en) 2009-03-26
EP1652842A1 (en) 2006-05-03
AU2004260756B2 (en) 2010-03-25
EA200600333A1 (ru) 2006-06-30
CA2518950A1 (en) 2005-02-10
EA010165B1 (ru) 2008-06-30
MXPA05011420A (es) 2005-12-12
US20070117856A1 (en) 2007-05-24
JP4335212B2 (ja) 2009-09-30
KR20060119705A (ko) 2006-11-24
US7470717B2 (en) 2008-12-30
EP1652842B1 (en) 2012-04-11
ATE553092T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
ATE553092T1 (de) Indazolderivate
UY25344A1 (es) Procedimiento para la preparacion de derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
DE602004023838D1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
JP2008535902A5 (pt)
CA2389545A1 (en) Chemokine receptor binding heterocyclic compounds
EP1643984A4 (en) USE OF PARTHENOLID DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
DK1056704T3 (da) Antitumormidler
ATE390923T1 (de) Topoisomerase-giftmittel
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
EA200701780A1 (ru) Противоопухолевое средство
EP1453507A4 (en) SOLUBILIZED TOPOISOMERASE GIFT MEDIUM
PE20060380A1 (es) Derivados de pirido-pirimidina en la prevencion y tratamiento de la proliferacion celular
JP2005531563A5 (pt)
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
BRPI0414778A (pt) 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer
MY144464A (en) Pyrazole derivatives as protien kinase modulators
TH77907A (th) การบำบัดของโรคการงอกขยายด้วยอนุพันธ์อีพอธิโลน และการฉายรังสี

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

Free format text: NOME ALTERADO DE: KYOWA HAKKO KOGYO CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.